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Abstract 
Background: Laparoscopic Sleeve Gastrectomy has become one of the most popular bariatric surgery types and 
helps treating not only obesity but also endocrinological diseases related to obesity. Therefore we aimed to evaluate 
the effects of laparoscopic sleeve gastrectomy on the treatment of type 2 diabetes.
Methods: All patients, who underwent morbid obesity surgery during 2013–2014 and had a HbA1c >6 % were 
included in this prospective study. Demographical data, usage of oral antidiabetic drugs or insulin were recorded, and 
laboratory findings as HbA1c and fasting plasma glucose were evaluated preoperatively and postoperatively at the 
6th and 12th months. Diabetes remission criteria were used to assess success of the surgical treatment.
Results: Totally 88 patients were included in this study. 55 patients were using oral antidiabetic drugs and 33 patients 
were using insulin. At the 6th month complete remission was observed in 80 (90.9 %), partial remission in 3 (3.4 %) 
and persistent diabetes in 5 (5.6 %) patients. At the 12th month complete remission was observed in 84 (95.4 %), 
partial remission in 1 (1.1 %) and persistent diabetes in 3 (3.4 %) patients.
Conclusions: This study indicated that laparoscopic sleeve gastrectomy surgery achieved a complete remission of 
diabetes in 95.4 % patients having type 2 diabetes during a 1 year fallow up period. However, complete remission of 
type 2 diabetes has been reported as 80 % during long term fallow up in the literature. In our opinion this rate may 
change with longer follow up periods and studies involving more patients suffering type 2 diabetes.
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Background
Every year 100,000 people die because of diabe-
tes in the world (http://www.who.int/bulletin/
volumes/86/10/07-048785/en/). Type 2 diabetes is com-
monly a component of metabolic disorders in the morbid 
obese patient (http://www.who.int/gho/ncd/risk_factors/
obesity_text/en/). It is estimated, that 35.8 million (2.3 %) 
people in the world are diagnosed to have overweight 
or obesity (http://apps.who.int/gho/data/node.main.
A865DIABETES?lang=en).
This serious health issue deserves to attract atten-
tion not only by internal specialists, but also by sur-
geons. Providentially recent studies reported surgical 
success up to 89  % in the treatment of type 2 diabetes 
in the morbid obese patients (Buchwald et  al. 2004). 
Bariatric surgery may fill the gap between medical 
treatment and complete remission in type 2 diabetes. 
However, bariatric surgery varies from minimal surgi-
cal interventions as laparoscopic gastric plication and 
laparoscopic sleeve gastrectomy (LSG) to major surgical 
interventions as laparoscopic Roux-en-Y Gastric By-pass 
(RYGBP), laparoscopic mini gastric bypass and duodenal 
switch procedures. Especially, achieves good long-term 
results including weight-loss maintenance, reduction of 
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comorbidities and improvement of quality of life (Cho 
et al. 2015).
Laparoscopic sleeve gastrectomy has gained popularity 
among surgeons, because it is a relative minimally inva-
sive procedure, easy to do and requires a short procedure 
time compared to gastric bypass (Torgersen et al. 2014).
The purpose of this study was to evaluate postoperative 
effects of LSG in morbid obese patients with type 2 dia-
betes, to present our one-year follow-up and to underline 
possible advantages of LSG.
Methods
This study was approved by a governmental ethical com-
mittee (Sisli Hamidiye Etfal Education and Training 
Hospital Ethical Committee Registration Number: 563). 
Verbal and written informed consent was obtained from 
all patients at the study beginning. Study design was a 
prospective clinical trial during the years 2013–2014 
including all patients, who applied to our bariatric sur-
gery polyclinic, because of morbid obesity and who had 
type 2 diabetes. Inclusion criteria were as follows: being 
morbid obese (BMI > 40 m2/kg), having type 2 diabetes 
and or having a glycosylated hemoglobin (HbA1c) >6 %, 
undergoing LSG. Excluded were patients who did not 
come to routine controls and who didn’t give informed 
consent for the study. Demographical data was recorded. 
HbA1c and fasting plasma glucose (FPG) were evaluated 
preoperatively and at the postoperatively 6th and 12th 
months. Patients were questioned, if they were taking 
insulin or oral antidiabetic drugs. Diabetes age was cal-
culated. After bariatric surgery diabetes remission crite-
ria of American Diabetes Association (ADA: complete 
remission is achieved when HbA1c is <6 % without any 
medication, partial remission is achieved when HbA1c 
is 6–6.5 % without any medication and not remission is 
a HbA1c  >  6.5  % without any medication or using any 
medication for diabetes regulation) were used to assess 
the success of the treatment (Mingrone et  al. 2012; 
Standards of Medical Care in Diabetes–2012 2012). 
Excess weight loss (EWL) was calculated for the 6th and 
12th months.
Surgical technique
All patients were given the “French” position before 
surgery, where the primary surgeon stood between the 
patient’s legs, first assistance stood at the primary sur-
geon’s right side and second assistance stood at his left 
side. Five ports were used: First a 10-mm trocar was 
placed 2 cm to the left of the midline above the umbili-
cus for optical view, then a 15-mm trocar was placed into 
the right midclaviculer-line, then a second 10-mm trocar 
was placed into the left midclavicular-line, afterwards a 
5-mm trocar was placed into the sub-xiphoid area as liver 
retractor and at last a second 5-mm trocar was placed 
into the left subcostal area to pull the stomach.
The stomach was completely mobilized from the 
greater omentum side, beginning at the line of incisura 
angularis by LigaSure™ (Covidien, USA). At first proxi-
mal dissection was performed up to the angle of His, dis-
tal dissection was performed until to the pylorus. Then 
a 36 F bougie was inserted by the anesthesiology team 
along the lesser curvature of the stomach. Antral resec-
tion was started 2–4 cm from the pylorus and continued 
up to 0.5–1  cm medial to the angle of His. Hemostasis 
was checked and provided by Endoclips™ (Covidien, 
USA). Possible leakage was checked with methylene blue 
in saline given through the bougie.
Statistical analysis
Statistical analyses were made with SPSS 22 (SPSS 
Inc.  Chicago). Data was presented as mean ±  standard 
deviation and categorical variables were expressed as 
frequencies.
Results
Totally 89 patients with type 2 diabetes, who underwent 
LSG in our clinic during the years 2013–2014 were eli-
gible for this study. One patient was excluded because 
she did not come to routine controls and 88 patients 
were included into the study. There were 28 (31.81  %) 
male and 60 (68.18  %) female patients with a mean age 
of 36 ±  9.35 (Table  1). The mean follow up of these 88 
patients was 16.09 ±  3.32  months (minimum 12–maxi-
mum 24 months).
Preoperative HbA1c of the 88 patients was 
7.33 ± 1.24 %, at the 6th month HbA1c was 5.5 ± 0.7 % 
and at the 12th month HbA1c was 5.2 ± 033 %. Preop-
erative FBG of the 88 patients was 166.85 ±  50.38  mg/
dL, at the 6th month FBG was 92.29 ± 23.28 mg/dL and 
at the 12th month FBG was 87.94 ± 7.02 mg/dL. Preop-
erative BMI of the 88 patients was 48.65 ±  7.71  kg/m2, 
BMI at the 6th month was 30 ± 3.28 kg/m2 and BMI at 
the 12th month was 26 ± 2.53 kg/m2 with a 6th month 
EWL of 68 ± 5.87 % and 12th month EWL of 81 ± 4.98 % 
(Table 2).
Table 1 Demographic data
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Preoperative 33 patients were using insulin, 35 patients 
were using oral antidiabetic drugs, 20 patients did not 
take any medications and were diagnosed to have type 2 
diabetes during preoperative assessment; endocrinology 
prescribed them to use oral antidiabetic drugs. Type 2 
diabetes age of 33 patients who were using insulin were 
39.42 ± 15.52 months, 35 patients who used oral antidia-
betic medicine were 20.2 ± 9.26 months and 20 patients 
who were started to use oral antidiabetic drugs during 
preoperative assessment were 9.6  ±  3.34  months (dia-
betes age was calculated from the diagnose date to the 
operation date, it takes about 6–18  months to have an 
operation appointment in our clinic). At the 6th month of 
postoperative follow-up 34 of 35 patients, who used oral 
antidiabetic drugs were in complete remission, 26 of 33 
patients who were using insulin were in complete remis-
sion. 2 of 33 patients were in partial remission and 5 of 
33 patients were not in remission. 19 of 20 patients who 
were prescribed to use oral antidiabetic drugs during 
preoperative period were in complete remission. One of 
20 patients who was started to use oral antidiabetic drugs 
during preoperative period was in partial remission.
At the 12th month of postoperative follow-up 29 of 33 
patients who were using insulin were in complete remis-
sion. One of 33 patients who were using insulin were in 
partial remission. Three of 33 patients, who were using 
insulin were not in remission. 54 of the 55 patients who 
were using oral antidiabetic drugs were in complete 
remission and 1 of 55 patients was in partial remission.
Totally, complete remission was observed in 90.9  %, 
partial remission was observed in 3.4  % and persistent 
diabetes in 5.6 % of the patients at the 6th month. At 12th 
month complete remission was observed in 94.3 %, par-
tial remission was observed in 2.2 % and persistent diabe-
tes in 3.4 % of the patients (Table 3).
Diabetes age of the 3 persistent diabetics was 
80.33 ± 8.02 months, diabetes age of the 2 diabetics hav-
ing partial remission was 57 ±  4.24  months and diabe-
tes age of the patients achieving complete remission was 
22.22 ± 11.71 months.
In our univariate logistic regression analysis, patient 
age, postoperative (PO) 6th month EWL, PO 12th month 
EWL, PO 6th month BMI and PO 12th month BMI were 
emerged as the decisive parameters (Table  4). In multi-
variate logistic regression analysis (forward type) patient 
age and PO 6th month EWL were emerged as the deci-
sive parameters (Table 5).  
In one patient postoperative leakage was observed and 
it was treated with percutaneous drainage inserted by a 
radiologist, self-expandable stents were not required. In 
another patient postoperative bleeding occurred and was 
treated with laparoscopic hematoma drainage. No perio-
perative or postoperative mortality was seen.
Discussion
Obesity is one of the major health problems in this era 
and endocrinological problems as type 2 diabetes may 
be one of its consequents (Standards of Medical Care in 
Table 2 Preoperative and postoperative patients’ data
FGL fasting plasma glucose, HbA1C glycosylated hemoglobin, EWL estimated 
weight loss






7.33 ± 1.24 5.5 ± 0.7 5.2 ± 0.33
FPG (mg/dL) 
Mean ± SD
166.85 ± 50.38 92.29 ± 23.42 87.94 ± 7.02
EWL (%) 
mean ± SD
68 ± 5.87 81 ± 4.98





Using insulin 78.78 87.87
Using oral  
antidiabetic drugs
96.36 98.18
Table 4 Factors affecting diabetes remission (univariate)
Univariate logictic regression analysis
Italic values are statistically meaningful (p<0.05)
p OR 95 % CI
Min Max
Patient age 0.003 1.320 1.097 1.589
BMI 0.068 1.093 0.993 1.203
DM AGE 0.055 1.271 0.994 1.623
Usage of insulin 0.079 7.448 0.795 69.774
Usage of OAD 0.079 0.134 0.014 1.258
PO 6th month EWL 0.007 0.756 0.617 0.926
PO 12th month EWL 0.003 0.649 0.490 0.859
Po 6th month BMI 0.005 1.446 1.119 1.870
PO 12th month BMI 0.004 2.073 1.260 3.408
Table 5 Factors affecting diabetes remission (multivariate)
Model: Patient Age, PO 6th month EWL, PO 12th month EWL, PO 6th month BMI, 
PO 12th month BMI
Multivariate logictic regression analysis (Forward)
p OR 95 % CI
Patient age 0.019 1.447 1.062 1.971
PO 6th month EWL 0.048 0.608 0.371 0.996
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Diabetes–2012). Adequate medical treatment of type 2 
diabetes is difficult to achieve, whereas bariatric surgery 
is proven to be a sufficient treatment method of not only 
weight loss but also endocrinological diseases in the mor-
bid obese patients (Buchwald et  al. 2009). In this study, 
our results supported this knowledge. We found, that 
complete remission in type 2 diabetes was observed after 
sleeve gastrectomy in a follow-up of 6 months as 90.9 % 
and 1 year as 95.4 %; previously 37.5 % of these patients 
were insulin dependent and 62.5 % were using oral anti-
diabetic drugs.
Previously reported diabetes remission rates change 
from 40 to 90 %, which vary related to the operation type, 
as diabetes remission is recently reported as 60–90  % 
in RYGBP, 86 % in bilio-pancreatic diversion (BPD); the 
long term results are 60 % diabetes remission in RYGBP 
and SLG and 50–70  % in insulin dependent diabetes 
(Boza et al. 2011; Cordera and Adami 2016; Miras et al. 
2014). Variations in diabetes remission rates may be 
explained by the usage of different remission criteria of 
ADA, which were upgraded in different years. We used 
the 2012 diabetes remission criteria (Standards of Medi-
cal Care in Diabetes–2012). The results in our study were 
quite better compared to the previous studies concerning 
diabetes remission (Miras et al. 2014; Rubino et al. 2010; 
Bayham et al. 2012). This may be parallel to the success of 
our hospital’s bariatric surgery team, as all patients in our 
study group were evaluated by this team, which is inter-
disciplinary consisting of endocrinologists, general sur-
geons, anesthesiologists, psychiatrists, pulmonologists, 
nutritionists and cardiologists. Morbid obese patients 
underwent surgery only after the approval of the bariatric 
surgery team. The patients were already treated by nutri-
tionists and endocrinologists for at least 1  year before 
being eligible for further evaluation of the bariatric sur-
gery team. After the surgical procedure patients were fol-
lowed up by nutritionists and surgeons closely. A strict 
diet was ordered postoperatively. Besides, our patients 
established an active social network between each other, 
their nutritionists and their surgeons. We believe, that 
sleeve gastrectomy with 36 F bougie, total antral and 
fundus resection together with postoperative close fol-
low-up, strict diet and motivating active social network 
helped to achieve our results.
Bariatric surgery includes a lot of surgical techniques, 
but laparoscopic interventions are preferred by surgeons, 
because of reduced complications, shorter postoperative 
recovery period and hospital stay. For similar reasons, 
among various surgical procedures LSG is a simple and 
quite effective surgical technique in the treatment of 
morbid obesity (Zhang et al. 2015). Recently laparoscopic 
sleeve gastrectomy has been reported to be effective in 
the complete remission of type 2 diabetes (Lemanu et al. 
2015). But larger sample sizes are necessary to make 
more accurate conclusions. In this study we followed 
up 88 patients having type 2 diabetes and reported their 
results after postoperative one-year follow-up.
During the preoperative assessment, diagnosis of type 
2 diabetes and also the treatment modality should be 
carefully questioned. Even if the patient does not have a 
history of type 2 diabetes preoperative laboratory tests 
should include HbA1c. This laboratory test may help 
to detect an undiagnosed of type 2 diabetes (Razi et  al. 
2015). In our clinical preoperative assessment proto-
col, we routinely check for elevated HbA1c, which also 
indicates whether diabetes is treated well and blood glu-
cose is in normal ranges. In our patients preoperatively 
HbA1c was 7.33 ±  1.24  %, HbA1c at the postoperative 
6th month check was 5.5 ± 0.7 % and HbA1c at the post-
operative 12th month check was 5.2 ± 0.33 %. One of the 
limitations in this study was, that we did not measure 
C-peptide preoperatively and postoperatively because of 
financial problems in our hospital.
Medical treatment status before surgery is another 
important factor to consider (Peterli et  al. 2009; Wu 
et  al. 2015). Preoperative insulin dependent 33 diabetic 
patients were in complete remission up to 87.87 % in our 
study and 55 patients receiving oral antidiabetic treat-
ment were in complete remission up to 98.18 %. Besides, 
we believe that the period of using insulin or oral anti-
diabetic drugs and the age of diabetes is also important 
on the treatment success of type 2 diabetes. Diabetes age 
of the 3 persistent diabetics was 80.33  ±  8.02  months, 
diabetes age of the 2 diabetics having partial remission 
was 57 ±  4.24  months and diabetes age of the patients 
achieving complete remission was 22.22 ± 11.71 months. 
It can be concluded, that the earlier type 2 diabetes is 
diagnosed, the better diabetes remission can be achieved. 
In our country laparoscopic sleeve gastrectomy is paid by 
health insurances only in patients with a BMI over 40 kg/
m2. In our opinion, obesity surgery should be done at 
lower BMI as <35  kg/m2 in type 2 diabetics to increase 
diabetes remission success (Kular et al. 2015).
It is still not known, how glycemic regulation after 
bariatric surgery works exactly. Weight loss is esti-
mated to be one of the strong factors, glycemic con-
trol success increases parallel to EWL (Lee et  al. 2013). 
Early regulation of the FGL is unclear. A lot of influenc-
ing factors have to be investigated. Our study data sup-
ported this knowledge, as preoperative BMI of the 88 
patients was 48.65 ± 7.71 kg/m2, BMI at the 6th month 
was 30  ±  3.28  kg/m2 and BMI at the 12th month was 
26 ± 2.53 kg/m2 with a 6th month EWL of 68 ± 5.87 % 
and 12th month EWL of 81 ± 4.98 %.
In previous studies shorter diabetes age was associated 
with higher diabetes remission rate (Yu et  al. 2015). In 
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our study although diabetes age of the 3 persistent dia-
betics was 80.33 ± 8.02 months, diabetes age of the 2 dia-
betics having partial remission was 57 ± 4.24 months and 
diabetes age of the patients achieving complete remission 
was 22.22 ± 11.71 months, univariate logistic regression 
analysis indicated that patient age, PO 6th month-EWL, 
PO 12th month EWL, PO 6th month BMI and PO 12th 
month BMI were emerged as the decisive parameters of 
DM remission and diabetes age was not statistically sig-
nificant. In multivariate logistic regression analysis (for-
ward type) patient age and PO 6th month-EWL were 
emerged as the decisive parameters of DM remission. In 
previous systemic review and meta-analysis EWL was 
not correlated with DM remission rate and in our study 
patient age and PO 6th month-EWL were emerged as 
the decisive parameters of diabetes remission (Cho et al. 
2015). These differences might be explained with a lit-
tle higher EWL, all patients were BMI  >  40  kg/m2 with 
preoperative BMI 48.65 ± 7.71 kg/m2, a younger patient 
population with age 36 ±  9.3, a strict diet and motivat-
ing active social network in our study compared to previ-
ous studies. Finally, only 5 patients were not in complete 
remission whereas 83 patients were in complete remis-
sion. This might have changed the regression analysis 
results.
 This study has promising results in the surgical treat-
ment of Type 2 DM with a 94.3  % complete remission 
rate. However, there are some limitations as short fallow 
up time (16.09 ± 3.32 months), small patient population 
(88 patients) and inclusion of new diagnosed patients (20 
patients) in this study. Collection of data is still continu-
ing in our clinic to observe long term results.1
Conclusion
Sleeve gastrectomy causes minimal physiological changes 
in the gastrointestinal tract and provides sufficient weight 
loss at the same time. Additional benefits are glycemic 
control and remission in type 2 diabetes. It seems to be a 
good solution to treat type 2 diabetics surgically.
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